May 29, 2025
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
May 06, 2025
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Apr 25, 2025
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Apr 22, 2025
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
Mar 05, 2025
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Feb 25, 2025
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
Feb 20, 2025
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
Dec 16, 2024
Jazz Pharmaceuticals Announces CEO Succession Plan
Dec 06, 2024
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
Dec 05, 2024
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
Dec 04, 2024
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
Dec 03, 2024
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
Nov 20, 2024
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 19, 2024
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
Nov 06, 2024
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
Sep 16, 2024
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Sep 09, 2024
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
Sep 04, 2024
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
Aug 21, 2024
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
Jul 17, 2024
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024